2019 Q1 Form 10-Q Financial Statement
#000119312519138300 Filed on May 06, 2019
Income Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|
Balance Sheet
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $222.1M | $146.6M |
| YoY Change | 51.54% | 23.74% |
| Cash & Equivalents | $79.33M | $30.55M |
| Short-Term Investments | $142.8M | $116.0M |
| Other Short-Term Assets | $4.400M | $1.500M |
| YoY Change | 193.33% | 7.14% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $200.0K | $1.698M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $226.7M | $149.8M |
| YoY Change | 51.32% | 24.98% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $1.441M | $1.131M |
| YoY Change | 27.41% | 14.94% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $12.00M | $30.50M |
| YoY Change | -60.66% | -2.24% |
| Other Assets | $210.0K | $327.0K |
| YoY Change | -35.78% | -0.91% |
| Total Long-Term Assets | $14.68M | $31.97M |
| YoY Change | -54.07% | -1.69% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $226.7M | $149.8M |
| Total Long-Term Assets | $14.68M | $31.97M |
| Total Assets | $241.4M | $181.8M |
| YoY Change | 32.79% | 19.29% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.293M | $449.0K |
| YoY Change | 187.97% | -45.18% |
| Accrued Expenses | $13.92M | $7.195M |
| YoY Change | 93.52% | 5.67% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $66.11M | $76.64M |
| YoY Change | -13.74% | 80.33% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $19.71M | $4.700M |
| YoY Change | 319.45% | |
| Other Long-Term Liabilities | $733.0K | $337.0K |
| YoY Change | 117.51% | 291.86% |
| Total Long-Term Liabilities | $20.45M | $337.0K |
| YoY Change | 5967.36% | 291.86% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $66.11M | $76.64M |
| Total Long-Term Liabilities | $20.45M | $337.0K |
| Total Liabilities | $160.7M | $156.2M |
| YoY Change | 2.87% | 47.32% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$386.4M | -$345.9M |
| YoY Change | 11.71% | 10.51% |
| Common Stock | $467.1M | $371.8M |
| YoY Change | 25.63% | 3.43% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $80.64M | $25.53M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $241.4M | $181.8M |
| YoY Change | 32.79% | 19.29% |
Cashflow Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
79333000 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
28088000 | |
| CY2019Q1 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
167000 | |
| CY2018Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
2058000 | |
| CY2019Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4399000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2342000 | |
| CY2019Q1 | us-gaap |
Assets Current
AssetsCurrent
|
226676000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
181384000 | |
| CY2019Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1441000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1536000 | |
| CY2019Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
210000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
390000 | |
| CY2019Q1 | us-gaap |
Assets
Assets
|
241357000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
183310000 | |
| CY2019Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12865000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12969000 | |
| CY2019Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
66108000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
64396000 | |
| CY2019Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
19714000 | |
| CY2018Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
19689000 | |
| CY2019Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
74451000 | |
| CY2018Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
84100000 | |
| CY2019Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
445000 | |
| CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
387000 | |
| CY2019Q1 | us-gaap |
Liabilities
Liabilities
|
160718000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
168572000 | |
| CY2019Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2019Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
58000 | |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
51000 | |
| CY2019Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
467047000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
389398000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
16000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
16000 | |
| CY2019Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-4000 | |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-198000 | |
| CY2019Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-386446000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-374497000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
80639000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14738000 | |
| CY2019Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
241357000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
183310000 | |
| CY2019Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2019Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
57725915 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
50652238 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
57725915 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
50652238 | |
| CY2019Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
8327000 | |
| CY2018Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
9546000 | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
8327000 | |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
9546000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9856000 | |
| CY2019Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1121000 | |
| CY2018Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
613000 | |
| CY2018Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
19402000 | |
| CY2019Q1 | us-gaap |
Interest Expense
InterestExpense
|
542000 | |
| CY2018Q1 | us-gaap |
Interest Expense
InterestExpense
|
174000 | |
| CY2018Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4660000 | |
| CY2019Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
20855000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12528000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15354000 | |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14742000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5501000 | |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
579000 | |
| CY2018Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
439000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11949000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9417000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.23 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.19 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
52395 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
48853 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11949000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9417000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
194000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-183000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-11755000 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-9600000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
79267000 | |
| CY2018Q1 | us-gaap |
Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
|
-47331000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-183000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1128000 | |
| CY2018Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
473000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2206000 | |
| CY2018Q1 | ccxi |
Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
|
335000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
25532000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14738000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
194000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
2852000 | |
| CY2019Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
1174000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2662000 | |
| CY2019Q1 | ccxi |
Adjustments To Additional Paid In Capital Compensation Expense Related To Options Granted To Consultants
AdjustmentsToAdditionalPaidInCapitalCompensationExpenseRelatedToOptionsGrantedToConsultants
|
40000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
80639000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-11949000 | |
| CY2018Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-9417000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2702000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2541000 | |
| CY2019Q1 | us-gaap |
Depreciation
Depreciation
|
141000 | |
| CY2018Q1 | us-gaap |
Depreciation
Depreciation
|
111000 | |
| CY2019Q1 | ccxi |
Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
|
436000 | |
| CY2018Q1 | ccxi |
Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
|
366000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
|
-1891000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
|
-49392000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1778000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
83000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-180000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-32000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
327000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-951000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-1443000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-1372000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-8160000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
1061000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-18286000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
40948000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
46000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
32000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
75235000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
77941000 | |
| CY2019Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
65170000 | |
| CY2018Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
26900000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-5144000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-51073000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
73276000 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2573000 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1128000 | |
| CY2019Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
1174000 | |
| CY2018Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
473000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
74675000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
655000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
51245000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-9470000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
28088000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
40020000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
79333000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
30550000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
422000 | |
| CY2018Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
70000 | |
| CY2019Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2018Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<table cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-spacing: 0px; margin-bottom: 0px; margin-top: 0px; table-layout: fixed;;text-align:left;;width:100%;"><tr style="vertical-align: top;"><td style="overflow-wrap: break-word; vertical-align: top; width: 0in; padding: 0px;"></td><td style="overflow-wrap: break-word; vertical-align: top; width: 0.79in;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-left: 0in; text-indent: 0in; background: none; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div><div style="font-size: 10pt; font-family: "times new roman", times, serif; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="overflow-wrap: break-word; vertical-align: top;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-left: 0in; text-indent: 0in; background: none; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Business</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. The Company’s principal operations are in the United States and it operates in one segment. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unaudited Interim Financial Information </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, 2018 Condensed Consolidated Balance Sheet was derived from audited financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on March 11, 2019. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2019Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2019Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2019Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company invests in a variety of financial instruments and, by its policy, limits the amount of credit exposure with any one issuer, industry or geographic area. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are typically unsecured and are concentrated in the pharmaceutical industry and government sector. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies and government funded entities. The Company has not historically experienced any significant losses due to concentration of credit risk. </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 12pt; text-indent: 0.79in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable consists of the following (in thousands): </div></div><div style="font-family: "times new roman", times, serif; font-size: 12pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 12pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="width: 76%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;margin-left :auto;margin-right :auto;"><tr><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;;width:;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 8pt; background: none;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;;width:;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 8pt; background: none;"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;;width:;"><div style="margin: 0in 0px 0.0001pt 0in; text-align: center; line-height: normal; font-family: "times new roman", times, serif; font-size: 8pt; background: none;"><div style="font-weight:bold;display:inline;">March 31,</div></div><div style="margin: 0in 0px 0.0001pt 0in; text-align: center; line-height: normal; font-family: "times new roman", times, serif; background: none; font-size: 8pt;"><div style="font-weight:bold;display:inline;">2019</div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;;width:;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 8pt; background: none;"> </div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;;width:;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 8pt; background: none;"> </div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 8pt;;vertical-align:bottom;;width:;"><div style="margin: 0in 0px 0.0001pt 0in; text-align: center; line-height: normal; font-family: "times new roman", times, serif; font-size: 8pt; background: none;"><div style="font-weight:bold;display:inline;">December 31,</div></div><div style="margin: 0in 0px 0.0001pt 0in; text-align: center; line-height: normal; font-family: "times new roman", times, serif; background: none; font-size: 8pt;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="padding: 0in; font-size: 8pt;;vertical-align:bottom;;width:;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 8pt; background: none;"> </div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 81%; padding: 0in; font-size: 10pt;;vertical-align:top;"><div style="margin: 0in 0px 0.0001pt 12.25pt; text-indent: -12.25pt; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;">Vifor (International) Ltd., and/or its affiliates, or collectively, Vifor</div></td><td style="background: rgb(204, 238, 255); width: 0.5%; padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"> </div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;">$</div></td><td style="background: rgb(204, 238, 255); width: 4%; padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; text-align: right; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;">167</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"> </div></td><td style="background: rgb(204, 238, 255); width: 7%; padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"> </div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;">$</div></td><td style="background: rgb(204, 238, 255); width: 4%; padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0px 0.0001pt 0in; text-align: right; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;">2,058</div></td><td style="background: rgb(204, 238, 255); width: 0.5%; padding: 0in; font-size: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0px 0px 0in; line-height: normal; font-family: "times new roman", times, serif; font-size: 10pt; background: none;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px; background: none;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div><div style="clear: both; max-height: 0px;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 1pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 1pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
11625436 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12519990 | |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
229997000 | |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
38000 | |
| CY2019Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
42000 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
229993000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
175124000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
198000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
174926000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
75248000 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
142777000 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
11968000 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
229993000 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
26030000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
148896000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
174926000 | |
| CY2019Q1 | ccxi |
Available For Sale Securities Debt Maximum Maturities Period
AvailableForSaleSecuritiesDebtMaximumMaturitiesPeriod
|
less than two years | |
| CY2019Q1 | us-gaap |
Cash
Cash
|
4100000 | |
| CY2018Q4 | us-gaap |
Cash
Cash
|
2100000 | |
| CY2019Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2019Q1 | us-gaap |
Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
|
0 | |
| CY2019Q1 | us-gaap |
Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q1 | ccxi |
Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
|
8220000 | |
| CY2018Q4 | ccxi |
Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
|
8466000 | |
| CY2019Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1460000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2767000 | |
| CY2019Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
779000 | |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
811000 | |
| CY2019Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12865000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12969000 | |
| CY2019Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1049000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
925000 | |
| CY2019Q1 | us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
20000000 | |
| CY2017Q4 | us-gaap |
Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
|
0.0805 | |
| CY2019Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
268000 | |
| CY2018Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
268000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1080000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
501000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1581000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
100000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1481000 | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y1M6D | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.110 | |
| CY2019Q1 | us-gaap |
Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
|
The Company received a discounted lease rate during the first year of the agreement. | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
236000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
8160000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
-896000 | |
| CY2016Q2 | ccxi |
Upfront Payment Received
UpfrontPaymentReceived
|
78000000 | |
| CY2016Q2 | ccxi |
Non Refundable Up Front Payment Received
NonRefundableUpFrontPaymentReceived
|
85000000 | |
| CY2016Q2 | ccxi |
Non Refundable Upfront Payments Allocated For Issuance Of Common Stock
NonRefundableUpfrontPaymentsAllocatedForIssuanceOfCommonStock
|
7000000 | |
| CY2016Q2 | ccxi |
Non Refundable Upfront Payment Received In Equity Investment Shares
NonRefundableUpfrontPaymentReceivedInEquityInvestmentShares
|
3333333 | |
| CY2016Q2 | ccxi |
Non Refundable Upfront Payments Allocated For Issuance Of Common Stock Per Share Value
NonRefundableUpfrontPaymentsAllocatedForIssuanceOfCommonStockPerShareValue
|
2.10 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1708516 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
10720200 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.39 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
2000000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
|
1529886 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1384133 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
11.44 | |
| CY2019Q1 | ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
|
107619 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
485012 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
5.88 | |
| CY2019Q1 | ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Expired Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpiredOrForfeited
|
584832 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
578165 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
6.85 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2871081 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
11041156 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
55107905 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
10648497 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
8.91 | |
| CY2019Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P6Y3M14D | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
53745822 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
7200618 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
8.56 | |
| CY2019Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y | |
| CY2019Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
39078897 | |
| CY2019Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y4M24D | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1062000 | |
| CY2019Q1 | ccxi |
Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
|
239000 | |
| CY2019Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
4967000 | |
| CY2019Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
1301000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
73276000 | |
| CY2019Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1301000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
6491196 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.96 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
0 | |
| CY2018Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
0 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12969000 | |
| CY2019Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
13924000 | |
| CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
387000 | |
| CY2019Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
733000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1481000 | |
| CY2019Q1 | ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized
|
0 | |
| CY2019Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1293000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
966000 | |
| CY2019Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
51950000 | |
| CY2018Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
50461000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1357000 | |
| CY2019Q1 | us-gaap |
Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
|
Advances under the Credit Facility bear an interest rate equal to the greater of either (i) 8.05% plus the prime rate as reported from time to time in The Wall Street Journal minus 4.75%, and (ii) 8.05%. At March 31, 2019, the interest rate on the outstanding borrowings under the Credit Facility was 8.80%. For advances made under the first and second tranches, the Company will make interest-only payments through July 1, 2021, and will then repay the principal balance and interest on the advances in equal monthly installments after the interest-only period and continuing through December 1, 2022. For advances made under the third tranche, the Company will make interest-only payments for the first 30 months, and will then repay the principal balance and interest on the advances in equal monthly installments after the interest-only period with each advance repaid 48 months after it is drawn. | |
| CY2019Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2019Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2019Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2019-03-31 | |
| CY2019Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2019 | |
| CY2019Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2019Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
ChemoCentryx, Inc. | |
| CY2019Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001340652 | |
| CY2019Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2019Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2019Q1 | dei |
Trading Symbol
TradingSymbol
|
CCXI | |
| CY2019Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2019Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
| CY2019Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
58047961 | |
| CY2018Q4 | ccxi |
Operating Lease Obligation Current
OperatingLeaseObligationCurrent
|
0 | |
| CY2018Q4 | ccxi |
Operating Lease Obligation
OperatingLeaseObligation
|
387000 |
